close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Precision BioSciences, Inc. - Common Stock (NQ:DTIL)

3.800 +0.230 (+6.44%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Precision BioSciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences to Participate in Upcoming June Investor Conferences
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences to Report First Quarter Results on May 13, 2024
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
From Precision BioSciences
Via Business Wire
News headline image
Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy
From Precision BioSciences
Via Business Wire
News headline image
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness
From Precision BioSciences
Via Business Wire
News headline image
Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences to Effect a Reverse Stock Split
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Approval of First Clinical Trial Application of ARCUS Gene Insertion Program by Partner iECURE
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Publication in Nature Metabolism Supporting ARCUS® In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences to Present at Hep-DART 2023
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Sidoti Events, LLC’s Virtual November Micro-Cap Conference
Via ACCESSWIRE
News headline image
Precision BioSciences Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences to Present at Upcoming Sidoti Conference
From Precision BioSciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today